Plasminogen activator, but not systemic antibiotic therapy, prevents abscess formation in an experimental model of secondary peritonitis

Intra‐abdominal abscesses are sources of recurrent or ongoing abdominal sepsis. They are an important target for prevention and treatment during or after surgical treatment of peritonitis. Experimental data suggest that fibrinolytic therapy may be effective when antibiotics are not.

[1]  R. Bleichrodt,et al.  Both tissue-type plasminogen activator and urokinase prevent intraabdominal abscess formation after surgical treatment of peritonitis in the rat. , 2008, Surgery.

[2]  M. Sezik,et al.  An evaluation of normal saline and taurolidine on intra-abdominal adhesion formation and peritoneal fibrinolysis. , 2008, The Journal of surgical research.

[3]  M. Boermeester.  Surgical approaches to peritonitis , 2007, The British journal of surgery.

[4]  D. Gouma,et al.  Comparison of on-demand vs planned relaparotomy strategy in patients with severe peritonitis: a randomized trial. , 2007, JAMA.

[5]  M. Boermeester,et al.  EFFECTS OF INTRA-ABDOMINAL ADMINISTRATION OF RECOMBINANT TISSUE PLASMINOGEN ACTIVATOR ON COAGULATION, FIBRINOLYSIS AND INFLAMMATORY RESPONSES IN EXPERIMENTAL POLYMICROBIAL PERITONITIS , 2007, Shock.

[6]  R. Bleichrodt,et al.  Tissue-type plasminogen activator prevents formation of intra-abdominal abscesses after surgical treatment of secondary peritonitis in a rat model , 2007, International Journal of Colorectal Disease.

[7]  H. Tomita,et al.  Delayed recurrence of postoperative intra-abdominal abscess: an unusual case and review of the literature. , 2006, Surgical infections.

[8]  T. van der Poll,et al.  The urokinase plasminogen activator receptor is crucially involved in host defense during acute pyelonephritis. , 2006, Kidney international.

[9]  A. Nathens,et al.  Management of severe sepsis in the surgical patient. , 2006, The Surgical clinics of North America.

[10]  M. Boermeester,et al.  Peritoneal lavage with activated protein C alters compartmentalized coagulation and fibrinolysis and improves survival in polymicrobial peritonitis , 2006, Critical care medicine.

[11]  R. Bleichrodt,et al.  A peritonitis model with low mortality and persisting intra‐abdominal abscesses , 2006, International journal of experimental pathology.

[12]  R. Sauermann,et al.  Principles of Antibiotic Penetration into Abscess Fluid , 2006, Pharmacology.

[13]  P. Carmeliet,et al.  Endogenous Tissue-Type Plasminogen Activator Is Protective during Escherichia coli-Induced Abdominal Sepsis in Mice1 , 2006, The Journal of Immunology.

[14]  A. Gullo,et al.  Management of severe sepsis and septic shock: challenges and recommendations. , 2006, Critical care clinics.

[15]  M. Boermeester,et al.  Surgical Therapy Attenuates Abdominal and Extra-Abdominal Inflammation in Experimental Peritonitis , 2006, European Surgical Research.

[16]  J. Hamilton,et al.  The effect of tissue type-plasminogen activator deletion and associated fibrin(ogen) deposition on macrophage localization in peritoneal inflammation , 2006, Thrombosis and Haemostasis.

[17]  H. Medina-Franco,et al.  Molgramostim (GM-CSF) associated with antibiotic treatment in nontraumatic abdominal sepsis: a randomized, double-blind, placebo-controlled clinical trial. , 2006, Archives of surgery.

[18]  D. Leaper,et al.  Antibiotic regimens for secondary peritonitis of gastrointestinal origin in adults. , 2005, The Cochrane database of systematic reviews.

[19]  H. Lijnen,et al.  Issue Editorial Focus : Issue Editorial Focus , 2005 .

[20]  A. Bauhofer,et al.  Dependence of Positive Effects of Granulocyte Colony-stimulating Factor on the Antibiotic Regimen: Evaluation in Rats with Polymicrobial Peritonitis , 2004, World Journal of Surgery.

[21]  J. Siewert,et al.  Current and Future Concepts of Abdominal Sepsis , 2004, World Journal of Surgery.

[22]  J. Marshall,et al.  Intensive care unit management of intra-abdominal infection , 2003, Critical care medicine.

[23]  H. van Goor,et al.  Pathophysiology of intra‐abdominal adhesion and abscess formation, and the effect of hyaluronan , 2003, The British journal of surgery.

[24]  C. Coopersmith,et al.  Effects of Age on Mortality and Antibiotic Efficacy in Cecal Ligation and Puncture , 2003, Shock.

[25]  D. Gouma,et al.  Meta‐analysis of relaparotomy for secondary peritonitis , 2002, The British journal of surgery.

[26]  M. Schein.  Surgical management of intra-abdominal infection: is there any evidence? , 2002, Langenbeck's Archives of Surgery.

[27]  M. Jaff,et al.  Pharmacologic and clinical characteristics of thrombolytic agents. , 2002, Reviews in cardiovascular medicine.

[28]  B. Risberg,et al.  Plasminogen activators and inhibitors in peritoneal tissue , 1997, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[29]  L. Holmdahl.  The role of fibrinolysis in adhesion formation. , 1997, The European journal of surgery. Supplement. : = Acta chirurgica. Supplement.

[30]  M. Schein,et al.  Management of secondary peritonitis. , 1996, Annals of surgery.

[31]  H. van Goor,et al.  Gentamycin reduces bacteremia and mortality rates associated with the treatment of experimental peritonitis with recombinant tissue plasminogen activator. , 1995, Journal of the American College of Surgeons.

[32]  J. van der Meer,et al.  Effect of recombinant tissue plasminogen activator on intra-abdominal abscess formation in rats with generalized peritonitis. , 1994, Journal of the American College of Surgeons.

[33]  K. Barvels.  Thrombolytic agents. , 1991, MNA accent.

[34]  O. Rotstein,et al.  Prevention of intra-abdominal abscesses by fibrinolysis using recombinant tissue plasminogen activator. , 1988, The Journal of infectious diseases.